Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
EPZM > SEC Filings for EPZM > Form 8-K on 7-Jan-2014All Recent SEC Filings

Show all filings for EPIZYME, INC.

Form 8-K for EPIZYME, INC.


7-Jan-2014

Results of Operations and Financial Condition, Financial Statements and Exhibits


Item 2.02 Results of Operations and Financial Condition

On January 6, 2014, Epizyme, Inc. (the "Company") announced the achievement of a $25 million clinical proof of concept ("POC") milestone in its EPZ-5676 DOT1L inhibitor clinical program under its collaboration with Celgene Corporation and a $4 million development candidate milestone under its collaboration with GSK. In the press release announcing the milestones, the Company stated that it estimates that, with the Celgene POC milestone and the GSK development candidate milestone, the Company's total cash and accounts receivable at December 31, 2013 would be approximately $145 million. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Statements contained in this Form 8-K about the Company that are not purely historical may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates", "estimates," and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results to be materially different from those expressed or implied by these forward-looking statements. For example, the estimated total cash and accounts receivable at December 31, 2013 are preliminary and subject to change. Important factors that may cause or contribute to such differences include the factors set forth in the risk factors section of the Company's Quarterly Report on Form 10-Q filed on October 23, 2013. The forward-looking statements in this Form 8-K represent the Company's views as of the date of this Form 8-K. The Company specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this Form 8-K.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.



Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 Press release issued by the Company on January 6, 2014


  Add EPZM to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for EPZM - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.